Delving into the Latest Updates on Runer Ophthalmic Drugs (Guangzhou) Co., Ltd. with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Immune System Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

H1 receptor(Histamine H1 receptor)	1

Primary objective: To evaluate the effectiveness of 0.05% epinastine hydrochloride eye drops in the treatment of allergic conjunctivitis, using emedastine fumarate eye drops as a control. Secondary objective: To evaluate the safety of 0.05% epinastine hydrochloride eye drops in the treatment of allergic conjunctivitis.

Start Date22 May 2023

Sponsor / Collaborator

Runer Ophthalmic Drugs (Guangzhou) Co., Ltd.

100 Clinical Results associated with Runer Ophthalmic Drugs (Guangzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Runer Ophthalmic Drugs (Guangzhou) Co., Ltd.

Login to view more data

100 Deals associated with Runer Ophthalmic Drugs (Guangzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Runer Ophthalmic Drugs (Guangzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data